2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.06 Chen

PP01.06 Chen - Abstract

Pdf Summary

The study focused on patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) and brain metastases (BM), aiming to understand the clinicopathologic characteristics and outcomes associated with this lung cancer subtype. Among the 460 patients with KRASG12C-mutated NSCLC analyzed, 23.3% had confirmed BM. The majority of BM cases were found either at initial presentation or upon tumor progression. Patients with BM were predominantly female, White, and had a history of smoking. Symptoms of central nervous system (CNS) metastasis were present in many patients and correlated with the number and size of lesions. Patients with BM had a higher incidence of co-mutations in TP53, STK11, and KEAP1, with no notable differences in tumor mutation burden (TMB) or PD-L1 status. Common interventions for BM included stereotactic radiation, surgical resection, chemotherapy, and a combination of chemotherapy and immunotherapy. A significant number of patients who received BM interventions experienced BM recurrence. The findings suggest that patients with KRASG12C-mutated NSCLC and BM may benefit from targeted therapies tailored to their specific mutations. Further research involving larger studies including patients with CNS involvement is recommended to better understand treatment responses for this patient population.

Keywords

KRASG12C-mutated non-small cell lung cancer

brain metastases

clinicopathologic characteristics

outcomes

NSCLC subtype

central nervous system metastasis

co-mutations

interventions for brain metastases

treatment responses

targeted therapies